Neutrophil inhibitors to reduce inflammatory response

A compound having the structure:

• 64
• wherein X and Y are heteroatoms wherein at least X or Y is nitrogen wherein the nitrogen can be unsubstituted or substituted with a lower alkyl group;
• Z is selected from the group consisting of a carbon atom, two carbon atoms or a heteroatom;
• R is independently selected from the group consisting of alkyl, lower alkyl, aromatic ring, carbocyclic aliphatic ring, halo, haloalkyl, heteroalkyl, lower heteroalkyl, heteroaromatic ring, heterocyclic aliphatic ring, hydrogen, —OH, —NH2, —SH, —OCH3;
• R1 and R2 are independently, selected from the group consisting of alkyl, lower alkyl, aromatic ring, carbocyclic aliphatic ring, halo, haloalkyl, heteroalkyl, lower heteroalkyl, heteroaromatic ring, heterocyclic aliphatic ring, or hydrogen;
• L is selected from the group consisting of
• 65
• wherein A is selected from the group consisting of a branched or unbranched alkyl, a branched or unbranched lower alkyl, or A is a covalent bond;
• R3 is selected from the group consisting of alkyl, lower alkyl, aromatic ring, carbocyclic aliphatic ring, haloalkyl, heteroalkyl, lower heteroalkyl, heterocyclic aliphatic ring, or hydrogen;
• B is selected from the group consisting of alkyl, lower alkyl, haloalkyl, heteroalkyl, lower heteroalkyl or B is a covalent bond;
• G is nil, or a substituent that links R4 and R5 into a cyclic ring structure which may be a 5-10 atom aromatic, aliphatic, heteroaromatic, or heteroaliphatic ring structure, which is unsubtituted or substituted wherein R4 is a substituent at any position on the ring structure;
• if G is nil then, R4 and R5 are:
• R4 is:
• 66
• wherein Q is selected from the group consisting of a carbon atom,
• 67
• W is selected from the group consisting of —OH or —NHOH;
• R7 is selected from the group consisting of alkyl, lower alkyl, aromatic ring, heteroaromatic ring, carbocyclic aliphatic ring, heteroalkyl, lower heteroalkyl, heterocyclic aliphatic ring, hydrogen ora covalent bond;
• R5 is selected from the group consisting hydrogen, alkyl, lower alkyl, aromatic ring, carbocyclic aliphatic ring, halo, haloalkyl, heteroalkyl, lower heteroalkyl, heterocyclic aliphatic ring, —C2H4— aromatic ring, —C2H4-carbocyclic aliphatic ring, —C2H4-heterocyclic aliphatic ring, —C2H4—Ph, —CH2-aromatic ring, —CH2-carbocyclic aliphatic ring, —CH2-heterocyclic aliphatic ring, —CH2Ph;
• R6 is selected from the group consisting of alkyl, lower alkyl, aromatic ring, carbocyclic aliphatic ring, halo, haloalkyl, heteroalkyl, lower heteroalkyl, heterocyclic aliphatic ring, hydrogen,, or any R4 group;
• optical isomers, diastereomers, and enantiomers thereof, and mixtures thereof, and pharmaceutically-acceptable salts, hydrates, biohydrolyzable amides, esters, and imides thereof.